In the Asia-Pacific region, PacBio recorded revenues of $8.9 million, reflecting a 33% decline year over year. The sequential growth in consumables was offset by lower Revio placements.

https://www.tipranks.com/news/the-fly/arcus-says-new-data-demonstrated-best-in-class-potential-for-casdatifan Canaccord reiterates a Buy rating on PacBio (PACB) with ...

Pacific Biosciences of California emphasized its strategic focus on expanding HiFi sequencing through product innovations like Vega and Revio. While macroeconomic uncertainties and academic ...

Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price target following the company’s Q4 report. The firm says that although PacBio forecasts modest sales growth in 2025, it remains ...

MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee ...

SoftBank disclosed a 20.45M share position in PacBio (PACB) and 14.67M share position in Recursion Pharmaceuticals (RXRX) in a regulatory filing detailing its holdings as of December 31 ...

Todd Friedman; Senior Director of Investor Relations; Pacific Biosciences of California Inc Christian Henry; President, Chief Executive Officer, Director; Pacific Biosciences of California Inc Michele ...